Investigating how blocking a specific protein can help treat multiple myeloma
Core transcriptional regulators of malignant stem cell generation in multiple myeloma
This study is looking at how blocking a protein called IRF4 might help improve treatments for multiple myeloma, a type of blood cancer, by stopping the growth of harmful stem cells and making standard therapies work better for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11003870 on NIH RePORTER |
What this research studies
This research focuses on understanding how inhibiting a protein called interferon regulatory factor-4 (IRF4) can disrupt the activation of stem cell pathways in multiple myeloma, a type of blood cancer. The researchers aim to combine this inhibition with standard treatments to reduce the disease burden and prevent the generation of malignant stem cells. By exploring the role of IRF4 in the survival of myeloma cells, the study seeks to identify new therapeutic strategies that could improve patient outcomes. The approach includes using novel RNA-targeted therapies to directly inhibit IRF4, which has been challenging with traditional methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma who are experiencing relapses or have not responded well to standard treatments.
Not a fit: Patients with early-stage multiple myeloma or those who are not yet undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for multiple myeloma, potentially reducing relapse rates and improving survival.
How similar studies have performed: While targeting transcription factors like IRF4 is a novel approach, similar strategies in other cancers have shown promise, indicating potential for success in this area.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Crews, Leslie a — University of California, San Diego
- Study coordinator: Crews, Leslie a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.